The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

Inclusion Criteria: * Age 50-75 years old, male or female * Able to understand the rationale of the clinical trial and sign informed consent form (ICF) * Diagnosis of Parkinson's Disease in accordance with the MDS clinical diagnostic criteria for Parkinson's disease (2015) * Diagnosis of Parkinson's Disease made between 4 to 20 years ago * Medically suitable for neurosurgery under anesthesia and able to participate in Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scan. * Hoehn-Yahr staging for "off" episodes is 2.5 to 4 * The MDS-UPDRS Part III (MDS-UPDRS-III) score in the "off" state \> 35, and positive for the Acute Levodopa Challenge Test (ALCT) * Acceptable laboratory test results during screening and prior to transplantation Exclusion Criteria: * Atypical Parkinsonism * Patients who have had previous pallidotomy, deep brain stimulation (DBS) surgery, striatal or extrapyramidal surgery, brain stereotaxy or other brain surgery; as well as other surgical procedures that are judged by the investigator to affect patient's participation in this study * Patients who have a previous head CT/MRI examination showing cerebral trauma, vascular malformation, hydrocephalus, brain tumor, etc., and patients who have brain imaging abnormalities in the striatum or other brain areas leading to a significantly increased risk for surgery. * Patients with a history of severe cardiovascular and cerebrovascular diseases * Patients with a history of malignant tumors …